Radiologic Features of T10 Paravertebral Muscle Sarcopenia: Prognostic Factors in COVID-19.
COVID-19
Chest computed tomography
Cross-sectional anatomy
Muscle mass
Prognostic factors
SAR-CoV-2
Journal
Journal of clinical medicine research
ISSN: 1918-3003
Titre abrégé: J Clin Med Res
Pays: Canada
ID NLM: 101538301
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
28
05
2023
accepted:
12
07
2023
medline:
14
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
Sarcopenia, defined as a small cross-sectional area (CSA) in computed tomography (CT) measurements of skeletal muscles, serves as a disease severity marker in various clinical scenarios, including pulmonary conditions and critical illness. Another parameter of sarcopenia, the level of myosteatosis, reflected by the tissue's radiodensity, in the thoracic skeletal muscles group, has been linked to disease progression in coronavirus disease 2019 (COVID-19) patients. We hypothesize that CT-derived measurements of the skeletal muscle density (SMD) and the CSA of thoracic skeletal muscles can predict outcomes in COVID-19 pneumonia. We retrospectively reviewed the CT scans of 84 patients with COVID-19 pneumonia admitted to two of Greece's largest academic teaching hospitals between April 2020 and February 2021. CSA and SMD at the level of the T10 vertebra were measured using computational imaging methods. The patient population was stratified according to survival status and CT severity score (CT-SS). Correlations were drawn between the radiologic features of sarcopenia, CT severity subgroups, serum inflammatory markers, and adverse events, e.g., death and intubation. Thoracic muscles' CSA measurements correlate with CT-SS and prominent inflammatory markers, such as white blood cell (WBC), C-reactive protein (CRP), fibrinogen, and D-dimers. Moreover, according to linear regression analysis, CSA seems to predict CT-SS variation significantly (β = -0.266, P = 0.018). CSA proved to differ significantly across survivors (P = 0.027) but not between CT severity categories and intubation subgroups. The AUC (area under the curve) of the receiver operating characteristic (ROC) curve for the predictive value of thoracic muscles' CSA in mortality is 0.774 (95% confidence interval (CI): 0.66 - 0.83, P < 0.000). The optimal cut-off value (Youden index = 0.57) for mortality prognosis, with a sensitivity of 66.7% and a specificity of 88.9%, is 15.55. Thoracic muscles' SMD analyses did not reveal any significant correlations. Easy to obtain and accurately calculated, radiologic features can provide a reliable alternative to laboratory methods for predicting survival in COVID-19. Thoracic muscles' CSA measurement in the level of the T10 vertebra, an acclaimed prognostic imaging assessment that relates directly to CT-SS and inflammatory markers in COVID-19 pneumonia, is a fairly specific tool for survival prognosis.
Sections du résumé
Background
UNASSIGNED
Sarcopenia, defined as a small cross-sectional area (CSA) in computed tomography (CT) measurements of skeletal muscles, serves as a disease severity marker in various clinical scenarios, including pulmonary conditions and critical illness. Another parameter of sarcopenia, the level of myosteatosis, reflected by the tissue's radiodensity, in the thoracic skeletal muscles group, has been linked to disease progression in coronavirus disease 2019 (COVID-19) patients. We hypothesize that CT-derived measurements of the skeletal muscle density (SMD) and the CSA of thoracic skeletal muscles can predict outcomes in COVID-19 pneumonia.
Methods
UNASSIGNED
We retrospectively reviewed the CT scans of 84 patients with COVID-19 pneumonia admitted to two of Greece's largest academic teaching hospitals between April 2020 and February 2021. CSA and SMD at the level of the T10 vertebra were measured using computational imaging methods. The patient population was stratified according to survival status and CT severity score (CT-SS). Correlations were drawn between the radiologic features of sarcopenia, CT severity subgroups, serum inflammatory markers, and adverse events, e.g., death and intubation.
Results
UNASSIGNED
Thoracic muscles' CSA measurements correlate with CT-SS and prominent inflammatory markers, such as white blood cell (WBC), C-reactive protein (CRP), fibrinogen, and D-dimers. Moreover, according to linear regression analysis, CSA seems to predict CT-SS variation significantly (β = -0.266, P = 0.018). CSA proved to differ significantly across survivors (P = 0.027) but not between CT severity categories and intubation subgroups. The AUC (area under the curve) of the receiver operating characteristic (ROC) curve for the predictive value of thoracic muscles' CSA in mortality is 0.774 (95% confidence interval (CI): 0.66 - 0.83, P < 0.000). The optimal cut-off value (Youden index = 0.57) for mortality prognosis, with a sensitivity of 66.7% and a specificity of 88.9%, is 15.55. Thoracic muscles' SMD analyses did not reveal any significant correlations.
Conclusions
UNASSIGNED
Easy to obtain and accurately calculated, radiologic features can provide a reliable alternative to laboratory methods for predicting survival in COVID-19. Thoracic muscles' CSA measurement in the level of the T10 vertebra, an acclaimed prognostic imaging assessment that relates directly to CT-SS and inflammatory markers in COVID-19 pneumonia, is a fairly specific tool for survival prognosis.
Identifiants
pubmed: 37575354
doi: 10.14740/jocmr4963
pmc: PMC10416190
doi:
Types de publication
Journal Article
Langues
eng
Pagination
368-376Informations de copyright
Copyright 2023, Schinas et al.
Déclaration de conflit d'intérêts
None to declare.
Références
Eur J Radiol. 2020 Oct;131:109271
pubmed: 32942198
Eur J Radiol. 2021 Dec;145:110031
pubmed: 34801878
Radiology. 2021 Aug;300(2):E328-E336
pubmed: 33724065
Anticancer Res. 2019 Sep;39(9):4603-4612
pubmed: 31519557
Osteoporos Int. 2010 Apr;21(4):543-59
pubmed: 19779761
Emerg Med J. 2022 Jan;39(1):63-69
pubmed: 34548413
Pathogens. 2022 Mar 02;11(3):
pubmed: 35335635
Phys Ther. 1998 Jun;78(6):602-10; discussion 611-2
pubmed: 9626272
Ann Lab Med. 2021 Nov 1;41(6):540-548
pubmed: 34108281
Clin Nutr. 2023 Feb;42(2):102-107
pubmed: 36521254
Scand J Public Health. 2022 Aug;50(6):671-675
pubmed: 34903101
Acad Radiol. 2021 Feb;28(2):166-172
pubmed: 33281041
Radiol Cardiothorac Imaging. 2020 Mar 30;2(2):e200047
pubmed: 33778560
Clin Transplant. 2014 Oct;28(10):1092-8
pubmed: 25040933
Eur Respir Rev. 2019 Nov 13;28(154):
pubmed: 31722892
Crit Rev Oncol Hematol. 2020 Jan;145:102839
pubmed: 31877534
PLoS One. 2021 Mar 16;16(3):e0248358
pubmed: 33725003
Respir Res. 2019 Feb 15;20(1):35
pubmed: 30767787
J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):e110-e116
pubmed: 33780535
Clin Nutr. 2022 Dec;41(12):2965-2972
pubmed: 34465493
Radiology. 2016 Feb;278(2):563-77
pubmed: 26579733
Sci Rep. 2019 Dec 13;9(1):19117
pubmed: 31836824
J Cachexia Sarcopenia Muscle. 2022 Feb;13(1):159-168
pubmed: 35018725
Front Nutr. 2022 Jul 04;9:925606
pubmed: 35859753
Acad Radiol. 2020 May;27(5):609-613
pubmed: 32204990
J Anesth. 2016 Oct;30(5):884-90
pubmed: 27376823
Age Ageing. 2019 Jul 1;48(4):601
pubmed: 31081853
J Digit Imaging. 2021 Apr;34(2):297-307
pubmed: 33604807
Radiol Res Pract. 2021 Jan 06;2021:6697677
pubmed: 33505722
Sci Rep. 2022 Apr 19;12(1):6443
pubmed: 35440794
J Am Med Dir Assoc. 2016 Aug 1;17(8):675-7
pubmed: 27470918
Clin Nutr. 2022 Dec;41(12):2918-2923
pubmed: 35140034
Tomography. 2022 Feb 08;8(1):414-422
pubmed: 35202199
Int J Endocrinol. 2021 May 21;2021:5563960
pubmed: 34113379
Radiology. 2020 Aug;296(2):E115-E117
pubmed: 32073353
Clin Nutr. 2022 Dec;41(12):3007-3015
pubmed: 34147286
Clin Geriatr Med. 2017 Feb;33(1):17-26
pubmed: 27886695
Radiology. 2020 Jun;295(3):715-721
pubmed: 32053470
J Heart Lung Transplant. 2014 Dec;33(12):1203-12
pubmed: 25044057